Adial Pharmaceuticals Inc (NASDAQ:ADIL)’s stock price traded up 7.6% during trading on Wednesday . The stock traded as high as $1.93 and last traded at $1.69, 334,938 shares traded hands during mid-day trading. An increase of 42% from the average session volume of 235,416 shares. The stock had previously closed at $1.57.
Several equities research analysts have recently commented on the stock. ValuEngine upgraded shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Adial Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 11th. Finally, Maxim Group set a $5.00 price target on shares of Adial Pharmaceuticals and gave the company a “buy” rating in a report on Friday, June 7th.
The firm’s fifty day moving average price is $1.67 and its 200 day moving average price is $2.32. The firm has a market cap of $16.49 million, a P/E ratio of -0.66 and a beta of 0.11.
About Adial Pharmaceuticals (NASDAQ:ADIL)
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis.
Further Reading: What are the Benefits of Index Funds?
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.